Novartis AG continues to create waves in the financial market with its consistent performance. While some entities, like Mengis Capital Management Inc and US Bancorp DE, have lowered their stake, a number of prominent firms, including Baldwin Wealth Partners LLC and Leo Wealth LLC, have increased their holdings, demonstrating the confidence in Novartis's continued growth. The pharmaceutical giant also garnered success from its Cosentyx discount strategy, as well as its FDA approval for Rhapsido. To top it all, the company notched a one-year high, affirming its strong trading volume and maintaining its standing as an excellent value stock. Negative assessments came from Barclays, who reconfirmed their sell rating, and Goldman Sachs, who rendered the stock as overvalued. Despite this, Novartis continues its upward trajectory, even acquiring biopharmaceutical firm, Regulus Therapeutics. The success of Novartis is also evident in CFO's retirement following its strong Q2 performance. The firm is off to a strong momentum in the long-term, despite the 4.6% dip hinting at potential opportunity in 2025.
Novartis Stocks News Analytics from Fri, 09 May 2025 07:00:00 GMT to Sat, 11 Oct 2025 13:19:05 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor 2
